Transplantation immunology and the gut

  • F. Shanahan
Part of the Immunology and Medicine Series book series (IMME, volume 31)


The full spectrum of transplantation immunologic reactions and complications associated with immune suppression, opportunistic infections, and mucosal injury from chemoradiation induction protocols, may be observed within the gastrointestinal tract. In addition to being a site of rejection reactions (host-versus-graft) in the setting of intestinal transplantation, the gastrointestinal tract is also a major target organ in graftversus-host (GvH) reactions, in patients undergoing other forms of organ transplantation, particularly bone marrow transplantation. A comprehensive analysis of modern concepts in transplantation immunology is beyond our scope here and an overview of those aspects particularly pertinent to the gastrointestinal tract is presented.


Bone Marrow Transplantation Intestinal Transplantation Intestinal Failure Herpes Simplex Virus Thymidine Kinase Immune Privilege 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Schraut WH. Immunologic aspects of small bowel transplantation. In: Targan SR, Shanahan F, editors. Immunology and immunopathology of the liver and gastrointestinal tract. New York: Igaku-Shoin, 1990; 611–645.Google Scholar
  2. 2.
    Shanahan F. The intestinal immune system. In: Johnson LR, Alpers D, Christensen J, Jacobson E, Walsh JH, editors. Physiology of the Gastrointestinal Tract 3rd edition. New. York: Raven Press, 1994 (3rd ed); 643–684.Google Scholar
  3. 3.
    Shanahan F. Mechanisms of immunologic sensation of intestinal contents. Am J Physiol (Gastrointest Liver Physiol) 2000; (in press)Google Scholar
  4. 4.
    Margreiter R. The history of intestinal transplantation. Transplantation Rev 1997;11:9–21.CrossRefGoogle Scholar
  5. 5.
    Quigley EMM. Small intestinal transplantation: reflections on an evolving approach to intestinal failure. Gastroenterology 1996;110:2009–2012.PubMedCrossRefGoogle Scholar
  6. 6.
    Grant D. Current results of intestinal transplantation: International Intestinal Transplantation Registry. Lancet 1996;347:1801–1803.PubMedCrossRefGoogle Scholar
  7. 7.
    Niv Y, Mor E, Tzakis AG. Small bowel transplantation - a clinical review. Am J Gastroenterol 1999;94:3126–3130.PubMedGoogle Scholar
  8. 8.
    Quigley EMM. Small intestinal transplantation - the ultimate therapy for IBD. In: Lembcke B, Kruis W, Sailor RB (eds), Systemic manifestations of IBD. The pending challenge for subtle diagnosis and treatment. Dordrecht, Kluwer Academic Publishers. 1998:313–318.Google Scholar
  9. 9.
    Abu-Elmagd K, Todo S, Tzakis A, Reyes J, Noor G, Furakawa H, Fung JJ, Demetris A, Starzl TE. Three years clinical experience with intestinal transplantation. J Am Coll Surg 1994;179:385–400.PubMedGoogle Scholar
  10. 10.
    Goulet O. Recent studies on small intestinal transplantation. Current Opinion Gastroenterology 1997;13:500–509.CrossRefGoogle Scholar
  11. 11.
    Lee RG, Nakamura K, Tsamandas AC, Abu-Elmagd K, Furukawa H, Hutson WR, Reyes J, Tabasco-Minguillan JS, Todo S, Demetris AJ. Pathology of human intestinal transplantation. Gastroenterology 1996;110:1820–1834.PubMedCrossRefGoogle Scholar
  12. 12.
    Murase N, Demetris AJ, Kim TG, Todo S, Fung JJ, Starzl TE. Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small bowel and liver grafts. Surgery 1990;108:880–889.PubMedGoogle Scholar
  13. 13.
    Arnaud-Battandier F, Salmon H, Vaiman M, Revillon Y, Galliz P, Olivier M, Ricour C. Small intestinal transplantation in swine with cyclosproine treatment: studies of the intestinal lymphoid populations. Transplant Proc 1985;17:1440–1441.Google Scholar
  14. 14.
    Grover R, Lear PA, Ingham Clark CL, Pockley AG, Wood RFM. Method for diagnosing rejection in small bowel transplantation. Br J Surg 1993;80:1024–1026.PubMedCrossRefGoogle Scholar
  15. 15.
    Iwaki Y, Starzl TE, Yagihashi A, et al. Replacement of donor lymphoid tissue in small bowel transplants. Lancet 1991;337:818–819.PubMedCrossRefGoogle Scholar
  16. 16.
    Nakamura K, Nalesnik M, Todo S, et al. Lymphocye traficking using in situ hybridization and physioanatomy of the intestinal immune system after human small bowel transplantation. Transplant Proc 1992;24:1197–1198.PubMedGoogle Scholar
  17. 17.
    Quan D, Grant DR, Zhong RZ, Zhang Z, Garcia BM, Jevnikar AM. Altered gene expression of cytokine, ICAM-1, and class II molecules precedes mouse intetinal allograft rejection. Transplantation 1994;58:808–816.PubMedGoogle Scholar
  18. 18.
    Langrehr JM, Banner B, Lee KKW, Schraut WH. Clinical course, morphology, and treatment of chronically rejecting small bowel allografts. Transplantation 1993;55:242–250.PubMedCrossRefGoogle Scholar
  19. 19.
    Lee KKW, Heeckt PF, Halfter WM, Schraut WM, Bauer AJ. Functional impairment of enteric smooth muscle and nerves caused by chronic intestinal allograft rejection regresses after FK506 rescue. Transplantation 1995;59:159–164.PubMedGoogle Scholar
  20. 20.
    Fontes P, Rao AS, Demetris AJ, et al. Augmentation with bone marrow of donor-cell chimerism in kidney, liver, heart and pancreas islet transplantation. Lancet 1994;344:151–155.PubMedCrossRefGoogle Scholar
  21. 21.
    Todo S, Tzakis A, Abu-Elmagd K, Reyes J, et al. Abdominal multivisceral transplantation. Transplantation 1995;59:234–240.PubMedGoogle Scholar
  22. 22.
    Starzl TE et al. The lost chord: microchimerism and allograft survivial. Immunol Today 1996;17:577–584.PubMedCrossRefGoogle Scholar
  23. 23.
    Sustento-Reodica N, Ruiz P, Rogers A, Viciana AL, Conn HO, Tzakis AG. Recurrent Crohn’s disease in transplanted bowel. Lancet 1997;349:688–691.PubMedCrossRefGoogle Scholar
  24. 24.
    Shanahan F, O’Sullivan GC, Collins JK. Genes, bacteria and T cells: ingredients for inflammatory bowel disease. Gastroenterology 1998;115:1595–1600.PubMedCrossRefGoogle Scholar
  25. 25.
    Lopez-Cubero SO, Sullivan KM, McDonald GB. Course of Crohn’s disease after allogeneic marrow transplantation. Gastroenterology 1998;114:433440.Google Scholar
  26. 26.
    James SP. Allogeneic bone marrow transplantation in Crohn’s disease. Gastroenterology 1998;114:596–606.PubMedCrossRefGoogle Scholar
  27. 27.
    McDonald GB, Shulman HM, Sullivan KM, Spencer GD. Intestinal and hepatic complications of human bone marrow transplantation. Part I. Gastorenterology 1986;90:460–477.Google Scholar
  28. 28.
    McDonald GB, Shulman HM, Sullivan KM, Spencer GD. Intestinal and hepatic compilations of human bone marrow transplantation. Part II. Gastroenterology 1986;90:770–784.Google Scholar
  29. 29.
    Shanahan F. Intestinal graft-versus-host disease. Gastroenterology 1998;115:220–222.PubMedCrossRefGoogle Scholar
  30. 30.
    Shanahan F, Targan S. Immunologic Diseases: Gastrointestinal manifestations of immunodeficiency, hypersensitivity, and graft versus host disease. In: Yamada T, Alpers D, Owyang C, Powell DW, Laine L, editors. Textbook of Gastroenterology. Philadelphia: JB Lippincott Company 1999; 2547–2563.Google Scholar
  31. 31.
    McDonald GB, Sale GE. The human gastrointestinal tract after allogeneic bone marrow transplantation. In: Sale GE, Shulman HM, editors. The pathology of bone marrow transplantation. New York: Masson, 1984:77–103.Google Scholar
  32. 32.
    Potten CS. Epithelial cell growth and differentiation II. Intestinal apoptosis. Am J Physiol (Gastrointest Liver Physiol) 1997; 36:G253–G257.Google Scholar
  33. 33.
    Epstein RJ, McDonald GB, Sale GE, Shulman HM, Thomas ED. The diagnostic accuracy of the rectal biopsy in acute graft-versus-host disease: A prospective study of thirteen patients. Gastroenterology 1980;78:764–771.PubMedGoogle Scholar
  34. 34.
    Weisbrot IM, Liber AF, Gordon BS. The effects of therapeutic radiation on colonic mucosa. Cancer 1975;36:931–940.PubMedCrossRefGoogle Scholar
  35. 35.
    Beschorner WE, Turnicky RP. Intestinal and hepatic manifestations of graftversus-host disease. In: Targan S, Shanahan F, editors. Immunology and immunopathology of the liver and gastrointestinal tract. New York: IgakuShoin 1989:589–609.Google Scholar
  36. 36.
    Davis RE, Smoller BR. T lymphocytes expressing HECA-452 epitope are present in cutaneous acute graft-versus-host disease and erythema multiforme, but not in acute graft-versus-host disease in gut organs. Am J Pathol 1992;141:691--698.PubMedGoogle Scholar
  37. 37.
    Krenger W, Hill GR, Ferrera JLM. Cytokine cascades in acute graft-versushost disease. Transplantation 1997;64:553–558.PubMedCrossRefGoogle Scholar
  38. 38.
    Serody JS, Cook DN, Kirby SL, Reap E, Shea TC, Freinger JA. Murine T lymphocytes incapable of producing macrophage inhibitory protein-1 are impaired in causing graft-versus-host disease across class I but not calss II major histocompatibility complex barrier. Blood 1999;93:43–50.PubMedGoogle Scholar
  39. 39.
    Brown GR, Lindberg G, Meddings J, Silva M, Beutler B, Thiele D. Tumor necrosis factor inhibitor ameliorates murine intestinal graft-versus-host disease. Gastroenterology 1999;116:593–601.PubMedCrossRefGoogle Scholar
  40. 40.
    Stüber E, von Freier A, Marinescu D, Fölsch U. Involvement of Ox40Ox4OL in the intestinal manifestations of the murine acute graft-versus-host disease. Gastroenterology 1998;115:1205–1215.PubMedCrossRefGoogle Scholar
  41. 41.
    Lin T, Brunner T, Tietz B, Madsen J, Bonfoco E, Reaves M, Huflejt M, Green DR. Fas ligand-mediated killing of intestinal intraepithelial lymphocytes. Participation in intestinal graft-versus-host disease. J Clin Invest 1998;101:570–577.PubMedCrossRefGoogle Scholar
  42. 42.
    Speiser DE, Bachmann MF, Frick TW, McKall-Faienza K, Griffiths E, Pfeffer K, Mak TW, Ohashi PS. TNF receptor p55 controls early acute graftversus-host disease. J Immunol 1997;158:5185–5190.PubMedGoogle Scholar
  43. 43.
    Murphy WJ, Welniak LA, Taub DD, Wiltrout RH, Taylor PA, Valiera DA, Kopf M, Young H, Longo DL, Blazer BR. Differential effects of the absence of interferon-y and IL-4 in acute graft-verus-host disease after allogeneic bone marrow transplantation in mice. J Clin Invest 1998;102:1742–1748.PubMedCrossRefGoogle Scholar
  44. 44.
    Murphy WJ, Blazer BR. New strategies for preventing graft-versus-host disease. Current Opin Immunol 1999;11:509–515.CrossRefGoogle Scholar
  45. 45.
    Cooke KR, Hill GR, Crawford JM, Bungard D, Brinson YS, Delmonte J, Ferrera JLM. Tumor necrosis factor-a production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graftversus-host disease. J Clin Invest 1998;102:1882–1891.PubMedCrossRefGoogle Scholar
  46. 46.
    Gallucci BG, Sale GE, McDonald GB, Epstein R, Shulman HM. The fine structure of human rectal epithelium in acute graft-versus-host disease. Am J Surg Pathol 1982;6:293–305.PubMedCrossRefGoogle Scholar
  47. 47.
    Cox GJ, Matsui SM, Lo RS, Hinds M, Bowden RA, Hackman RC, Meyer WG, Mori M, Tarr PI, Oshiro LS, Ludert JE, Meyers JD, McDonald GB. Etiology and outcome of diarrhea after marrow transplantation: a prospective study. Gastroenterology 1994;17:1398–1407.Google Scholar
  48. 48.
    McDonald GB, Bouvier M, Hockenbery DM, Stern JM, Gooley T, Farrand A, Murakami C, Levine DS. Oral beclomethasone dipropionate for treatment of intestinal graft-vs-host disease: a randomized, controlled trial. Gastroenterology 1998; 115:28–35.PubMedCrossRefGoogle Scholar
  49. 49.
    Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E, Hoffman RG, Jacobsen SJ, Marmont AM, McGlave PB, Messner HA, Rimm AA, Rozman C, Speck B, Tura S, Weiner RS, Bortin MM. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988;18:806–814.CrossRefGoogle Scholar
  50. 50.
    Kernan NA, Bordignon C, Heller G, Cunningham I, Castro-Malaspina H, Shank B, Flomenberg N, Burns J, Yang SY, Black P, Collins NH, O’Reilly U. Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: I. Analysis of risk factors and results of secondary transplants. Blood 1989;74:2227–2236.Google Scholar
  51. 51.
    Bonini C, Ferrari G, Verzeletti S, Servida P, Zappone E, Ruggieri L, Ponzoni M, Rossini S, Mavililo F, Traversari C, Bordignon C. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997;276:1719–1724PubMedCrossRefGoogle Scholar
  52. 52.
    Shlomchik WD, Couzens MS, Tang CB et al, Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999;285:412–415.PubMedCrossRefGoogle Scholar
  53. 53.
    McDonald GB, Sullivan M, Schuffler MD, Shulman HM, Thomas ED. Esophageal abnormalities in chronic graft-versus-host disease in humans. Gastroenterology 1981;80:914–921.PubMedGoogle Scholar
  54. 54.
    McDonald GB, Sullivan KM, Plumley TF. Radiographic features ofGoogle Scholar
  55. esophageal involvement in chronic graft-versus-host disease. Am J Roentgenol 1984;142:501–506.Google Scholar
  56. 55.
    Benigni A, Remuzzi G. Transplant tolerance: will genes protect the graft? Lancet 1998;351:1749–1751.PubMedCrossRefGoogle Scholar
  57. 56.
    Waldmann H. Transplantation tolerance - where do we stand? Nat Med 1999; 5:1245–1248.PubMedCrossRefGoogle Scholar
  58. 57.
    Matzinger P. Graft tolerance: a duel of two signals. Nat Med 1999;5:616617.Google Scholar
  59. 58.
    Ferguson TA, Green DR. T cells are just dying to accept grafts. Nat Med 1999;5:1231–1232.PubMedCrossRefGoogle Scholar
  60. 59.
    Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995;270:1189–1192.PubMedCrossRefGoogle Scholar
  61. 60.
    O’Connell J, Bennett MW, O’ Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: cancer as a site of immune privilege. Immunol Today 1999;20:46–52PubMedCrossRefGoogle Scholar
  62. 61.
    Swenson KM, ke B, Wang T, et al. Fas ligand gene transfer to renal allografts in rats: effects on allograft survival. Transplantation 1998;65:155160.Google Scholar
  63. 62.
    Kang S-M, Schneider DB, Lin Z, et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 1997;3:738–743.PubMedCrossRefGoogle Scholar
  64. 63.
    Allison J, Georgiou HM, Strasser A, Vaux DL. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci USA 1997;94:3943–3946.PubMedCrossRefGoogle Scholar
  65. 64.
    Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991–1045.PubMedCrossRefGoogle Scholar
  66. 65.
    Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999;5:686–693.PubMedCrossRefGoogle Scholar
  67. 66.
    Li Y, chang X, Zheng XX et al. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999; 5:1298–1302.PubMedCrossRefGoogle Scholar
  68. 67.
    Wells AD, Li XC, Li Y, et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 1999; 5:13031307.Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • F. Shanahan

There are no affiliations available

Personalised recommendations